M108
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for M108, covering 2024-02-28 to 2024-02-28. Get the full timeline:
Most recent: Clinical Trial Update: M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. [Phase 3]